Drug intelligence / Profile preview

lomustine + valproic acid

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of two drugs with a significant interaction. Lomustine (CCNU) is a lipophilic nitrosourea anticancer agent that undergoes hydrolysis to form reactive metabolites that alkylate and cross-link DNA. Valproic acid is an anticonvulsant that enhances GABAergic activity. When combined, valproic acid may impair lomustine metabolism and increase its toxicity, while lomustine may increase the toxic effects of valproic acid.

Targets

HDAC (HDAC family)DNA

Beyond the preview

Go deeper on lomustine + valproic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lomustine + valproic acid.

Explore the full profile